Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).

@article{Schechter2005InhibitionOH,
  title={Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).},
  author={Norman M. Schechter and Eun-Jung Choi and Zhe-Mei Wang and Yasushi Hanakawa and John R. Stanley and Ya'an Kang and Gary L Clayman and Arumugam Jayakumar},
  journal={Biological chemistry},
  year={2005},
  volume={386 11},
  pages={1173-84}
}
LEKTI is a 120-kDa protein that plays an important role in skin development, as mutations affecting LEKTI synthesis underlie Netherton syndrome, an inherited skin disorder producing severe scaling. Its primary sequence indicates that the protein consists of 15 domains, all resembling a Kazal-type serine protease inhibitor. LEKTI and two serine proteases belonging to the human tissue kallikrein (hK) family (hK5 and hK7) are expressed in the granular layer of skin. In this study, we characterize… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Human tissue kallikreins: a road under construction.

Clinica chimica acta; international journal of clinical chemistry • 2007
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…